GT199900066A - Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea. - Google Patents

Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea.

Info

Publication number
GT199900066A
GT199900066A GT199900066A GT199900066A GT199900066A GT 199900066 A GT199900066 A GT 199900066A GT 199900066 A GT199900066 A GT 199900066A GT 199900066 A GT199900066 A GT 199900066A GT 199900066 A GT199900066 A GT 199900066A
Authority
GT
Guatemala
Prior art keywords
estrogen receptor
parathyroid hormone
selective estrogen
southeast
combinations including
Prior art date
Application number
GT199900066A
Other languages
English (en)
Inventor
Hua Zhu Ke
David Duane Thompson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900066A publication Critical patent/GT199900066A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Abstract

ESTA INVENCION SE REFIERE A UNA COMBINACION FARMACEUTICA DE UN MODULADOR DEL RECEPTOR DE ESTROGENOS SELECTIVOS (SERM) Y HORMONA PARATIROIDEA (PTH) O UNO DE SUS FRAGMENTOS BIOLOGICAMENTE ACTIVOS QUE ESTIMULA LA FORMACION DE HUESO, AUMENTA LA MASA OSEA Y POTENCIA LOS EFECTOS RESTAURADORES DEL HUESO DE LA PTH. LA INVENCION TAMBIEN SE REFIERE A ESTUCHES QUE CONTIENEN TALES COMBINACIONES Y AL USO DE TALES COMBINACIONES PARA TRATAR LA FRAGILIDAD MUSCULOESQUELETICA, INCLUYENDO OSTEOPOROSIS, FRACTURAS Y AFECCIONES SIMILARES EN MAMIFEROS INCLUYENDO SERES HUMANOS.
GT199900066A 1998-06-16 1999-05-10 Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea. GT199900066A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8947998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
GT199900066A true GT199900066A (es) 2000-10-31

Family

ID=22217879

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900066A GT199900066A (es) 1998-06-16 1999-05-10 Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea.

Country Status (34)

Country Link
US (1) US6132774A (es)
EP (1) EP1094808A1 (es)
JP (1) JP2002518323A (es)
KR (1) KR20010052818A (es)
CN (1) CN1305373A (es)
AP (1) AP9901580A0 (es)
AR (1) AR018867A1 (es)
AU (1) AU3725999A (es)
BG (1) BG105125A (es)
BR (1) BR9911228A (es)
CA (1) CA2335078A1 (es)
CO (1) CO5070584A1 (es)
EA (1) EA200001199A1 (es)
GT (1) GT199900066A (es)
HN (1) HN1999000063A (es)
HR (1) HRP20000858A2 (es)
HU (1) HUP0102759A3 (es)
ID (1) ID26873A (es)
IL (1) IL139588A0 (es)
IS (1) IS5719A (es)
MA (1) MA26649A1 (es)
NO (1) NO20006313L (es)
NZ (1) NZ508039A (es)
OA (1) OA11566A (es)
PA (1) PA8471201A1 (es)
PE (1) PE20000644A1 (es)
PL (1) PL344982A1 (es)
SK (1) SK18922000A3 (es)
TN (1) TNSN99119A1 (es)
TR (1) TR200003567T2 (es)
UA (1) UA60367C2 (es)
WO (1) WO1999065482A1 (es)
YU (1) YU75800A (es)
ZA (1) ZA993972B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
US20020107230A1 (en) * 2000-12-22 2002-08-08 Waldon R. Forrest Methods and formulations for the treatment of female sexual dysfunction
US20030191096A1 (en) * 2002-04-03 2003-10-09 Leonard Thomas W. Method of hormonal therapy
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
US7919506B2 (en) 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
TW201043595A (en) * 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
DE102010027016A1 (de) 2010-07-09 2012-01-12 Universitätsklinikum Jena Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen
CN111067907A (zh) * 2018-10-18 2020-04-28 常州大学 孕激素在抑制血管内皮生长因子表达中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254595A (en) * 1988-12-23 1993-10-19 Elf Sanofi Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
KR20010052818A (ko) 2001-06-25
CO5070584A1 (es) 2001-08-28
PL344982A1 (en) 2001-11-19
NO20006313D0 (no) 2000-12-12
BR9911228A (pt) 2001-02-13
NZ508039A (en) 2003-03-28
US6132774A (en) 2000-10-17
AU3725999A (en) 2000-01-05
ZA993972B (en) 2000-12-15
IS5719A (is) 2000-11-21
CA2335078A1 (en) 1999-12-23
AP9901580A0 (en) 1999-06-30
BG105125A (en) 2001-11-30
HUP0102759A2 (hu) 2002-03-28
HN1999000063A (es) 2000-01-12
WO1999065482A1 (en) 1999-12-23
IL139588A0 (en) 2002-02-10
UA60367C2 (uk) 2003-10-15
TR200003567T2 (tr) 2001-06-21
NO20006313L (no) 2000-12-12
HRP20000858A2 (en) 2001-10-31
EP1094808A1 (en) 2001-05-02
EA200001199A1 (ru) 2001-04-23
OA11566A (en) 2004-05-26
MA26649A1 (fr) 2004-12-20
CN1305373A (zh) 2001-07-25
PA8471201A1 (es) 2000-09-29
AR018867A1 (es) 2001-12-12
PE20000644A1 (es) 2000-08-02
YU75800A (sh) 2003-12-31
ID26873A (id) 2001-02-15
JP2002518323A (ja) 2002-06-25
TNSN99119A1 (fr) 2005-11-10
HUP0102759A3 (en) 2002-12-28
SK18922000A3 (sk) 2001-09-11

Similar Documents

Publication Publication Date Title
GT199900066A (es) Combinaciones terapeuticas que comprenden un modulador del receptor de estrogenos selectivo y hormona paratiroidea.
GT199700141A (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas.
ES2178048T3 (es) Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis.
CL2004000674A1 (es) Sistema terapeutico transdermico que comprende al menos una sustancia activa farmaceutica, al menos un disruptor de la estructura y/o al menos un formador de estructura en una matriz comun.
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
ES2187830T3 (es) Uso de activadores de receptores del cntf (factor neurotrofico cil iar) para el tratamiento de la obesidad.
DK1382340T3 (da) Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporose
PT1143937E (pt) O e declinio rapido das concentracoes eficazes de droga no plasma formulacoes de libertacao controlada com um arranque rapid
MXPA05006670A (es) Administracion de capsaicinoides.
ES2167899T3 (es) Extractos de plantas para el tratamiento de resorcion osea incrementada.
ES2102921T3 (es) Utilizacion de derivados de la hormona estimuladora de los melanocitos de tipo alfa para estimular el crecimiento de los cabellos.
ES2036553T3 (es) Composiciones farmaceuticas que tienen actividad antineoplastica.
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
ES2116642T3 (es) Composicion farmaceutica para tratar la osteoporosis que contiene xantohumol.
GT200000077A (es) Sal mutua de amlodipino y atorvastatina
ES2183341T3 (es) Utilizacion cosmetica o dermatoloogica de esteroides 7-hidroxilados.
ATE443527T1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
GT199800091A (es) Formas de dosificacion de sertralina de liberacion retardada.
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
DK1272195T3 (da) Anvendelse af fulvestrant til behandling af resistent brystcancer
ES2173911T3 (es) Uso de glicosidos en vitamina d para el tratamiento o prevencion de la osteoporosis.
NO20025157D0 (no) Kreftterapi
NO20026055L (no) Farmasöytiske komponenter innbefattende humant paratyreoideahormon og farmasöytiske sammenstninger for nasal administrering inneholdendekomponentene
ES2130102T1 (es) Composicion cosmetica adelgazante que contiene un extracto de chrysanthellum indicum.